Teva Sees Innovative Revenue Potential Of $6 Billion to $7 Billion By 2030
Nov 11 (Reuters) - Teva Pharmaceutical Industries Limited TEVA.TA:
TEVA: SEES INNOVATIVE REVENUE POTENTIAL OF $6 BILLION -7 BILLION BY 2030
TEVA: FREE CASH FLOW TARGET OF MORE THAN $3.5 BILLION BY 2030
TEVA: EXPECTS TOTAL REVENUE OF MID-SINGLE-DIGIT GROWTH FROM 2026 TO 2030
Further company coverage: TEVA.TA